Detalhe da pesquisa
1.
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis.
Circulation
; 149(4): 293-304, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950893
2.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
; 387(12): 1089-1098, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36027570
3.
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Circulation
; 147(13): 1004-1013, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802715
4.
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
Circulation
; 148(22): 1735-1745, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632455
5.
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Circulation
; 148(9): 732-749, 2023 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366061
6.
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
Circulation
; 148(24): 1945-1957, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830208
7.
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Circulation
; 147(14): 1067-1078, 2023 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876483
8.
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Circulation
; 147(8): 624-634, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342789
9.
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Circulation
; 147(4): 284-295, 2023 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335517
10.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
N Engl J Med
; 385(10): 896-907, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215025
11.
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial.
Am Heart J
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740532
12.
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
J Card Fail
; 30(1): 104-110, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072105
13.
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
J Card Fail
; 30(4): 618-623, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122924
14.
Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial.
J Card Fail
; 30(4): 525-537, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820896
15.
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
J Card Fail
; 30(3): 436-448, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104937
16.
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Cardiovasc Diabetol
; 23(1): 49, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302936
17.
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification.
Diabet Med
; 41(2): e15200, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578188
18.
Heart Failure Subtypes and Cardiomyopathies in Women.
Circ Res
; 130(4): 436-454, 2022 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35175847
19.
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management.
Diabetes Obes Metab
; 26(5): 1567-1581, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328853
20.
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Diabetes Obes Metab
; 26(4): 1216-1223, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38116691